Sosei Group Corporation announced the appointment of Mr. Toshihiro Maeda as Chief Operating Officer (?COO?). Mr. Maeda joins from Bristol Myers Squibb (?BMS?), where he led a Business Unit and was instrumental in the post-merger integration of Celgene?s businesses and commercial strategies for the combined group in Japan. Mr. Maeda brings with him a breadth of global management and commercialization experience and a strong background rooted in the pharmaceutical industry.

Prior to BMS, he worked at Merck & Co in both Japan and the US where he held senior partnering and commercialization roles in its oncology and diabetes business units. He also worked at McKinsey and Company in Japan and the UK where he gained global business experience in healthcare industry. Mr. Maeda holds an MBA from The University of Chicago Booth School of Business in the US.

In this newly created role at Sosei Heptares, Mr. Maeda will lead the post-acquisition integration of Idorsia Pharmaceuticals Japan (?IPJ?), and global technical operations, including manufacturing, supply chain and quality assurance, for the enlarged business in Japan and the Asia-Pacific region.